Abstract
While immune checkpoint inhibitors (ICIs) have transformed standards of care and drastically improved patient prognoses in several malignant diseases, a range of immune related adverse events (irAEs) from ICIs have been observed. This case series describes the clinical course of three patients with unusual immune checkpoint-inhibitor (ICI) induced toxicities. These three patients developed carpal tunnel syndrome (CTS) while on ICI therapy. The first patient was a 79 year-old male who received neo-adjuvant chemo-immunotherapy and adjuvant immunotherapy (atezolizumab) for stage II-B lung adenocarcinoma, the second patient was a 70 year-old female who received immunotherapy only (nivolumab) for stage IV renal cell carcinoma and the third patient was a 71 year-old male who received adjuvant immunotherapy (nivolumab) for stage 2-A melanoma. The patients developed carpal tunnel syndrome with severe neuropathy as a result of therapy. All patients had complete symptomatic relief when treated with either corticosteroids or intravenous immunoglobulins for CTS.
Downloads
Most read articles by the same author(s)
- Walid Shalata, Alexander Yakobson, Ismaell Massalha, Aharon Y. Cohen, Iris M. Goldstein, Rachel Gibbs, Abu Saleh Omar, Mohnnad Asla, Yulia Dudnik, Ali Abu-Juma'a, Nir Peled, Keren Rouvinov, Unusual Adverse Effects of Immune Checkpoint Inhibitors: Autonomic Neuropathy, Palmoplantar Keratoderma, Reiter Syndrome & Myasthenia Gravis: A Case Series and Review of the Literature , International Journal of Innovative Research in Medical Science: Vol. 5 No. 11 (2020)
- Walid Shalata, Ismaell Massalha, Kayed Al-Athamen, Large B-Cell Lymphoma with T-Cell–Rich Background and Nodules Lacking Follicular Dendritic Cell Meshworks: A Case Report with Complete Response to Chemotherapy and a Review of the Literature , International Journal of Innovative Research in Medical Science: Vol. 5 No. 11 (2020)
Copyrights & License
This work is licensed under a Creative Commons Attribution 4.0 International License.